Login / Signup

Efficacy of Prolonged-Release Melatonin 2 mg (PRM 2 mg) Prescribed for Insomnia in Hospitalized Patients for COVID-19: A Retrospective Observational Study.

Carolina BolognaPasquale MadonnaEduardo Pone
Published in: Journal of clinical medicine (2021)
A significant increase in sleep hours and a reduction in delirium episodes occurs in hospitalized insomniac patients treated with PRM 2 mg, compared to untreated patients. Based on these preliminary results, we can assume that there are benefits of prolonged-release melatonin 2 mg in COVID-19 therapy.
Keyphrases
  • coronavirus disease
  • sars cov
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • sleep quality
  • peritoneal dialysis
  • physical activity
  • stem cells
  • patient reported
  • smoking cessation